Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel Sells 6,667 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel sold 6,667 shares of Enliven Therapeutics stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $21.44, for a total transaction of $142,940.48. Following the transaction, the chief operating officer now directly owns 323,310 shares in the company, valued at $6,931,766.40. The trade was a 2.02 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Anish Patel also recently made the following trade(s):

• On Friday, February 7th, Anish Patel sold 6,667 shares of Enliven Therapeutics stock. The shares were sold at an average price of $21.93, for a total transaction of $146,207.31.
• On Tuesday, January 7th, Anish Patel sold 21,700 shares of Enliven Therapeutics stock. The shares were sold at an average price of $24.18, for a total transaction of $524,706.00.

Enliven Therapeutics Stock Up 2.1 %

Shares of Enliven Therapeutics stock opened at $20.69 on Wednesday. Enliven Therapeutics, Inc. has a 12-month low of $10.90 and a 12-month high of $30.03. The stock has a market cap of $1.01 billion, a P/E ratio of -10.89 and a beta of 1.04. The business’s 50 day moving average is $21.76 and its 200-day moving average is $23.86.

Institutional Investors Weigh In On Enliven Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in ELVN. Polar Capital Holdings Plc raised its stake in shares of Enliven Therapeutics by 267.6% during the 4th quarter. Polar Capital Holdings Plc now owns 2,389,668 shares of the company’s stock worth $53,768,000 after purchasing an additional 1,739,668 shares in the last quarter. Boxer Capital Management LLC bought a new position in shares of Enliven Therapeutics during the 4th quarter worth approximately $15,106,000. FMR LLC boosted its stake in shares of Enliven Therapeutics by 10.6% during the 3rd quarter. FMR LLC now owns 6,296,179 shares of the company’s stock worth $160,804,000 after acquiring an additional 601,611 shares during the period. Lord Abbett & CO. LLC bought a new position in shares of Enliven Therapeutics during the 3rd quarter worth approximately $8,199,000. Finally, Janus Henderson Group PLC boosted its stake in shares of Enliven Therapeutics by 43.0% during the 3rd quarter. Janus Henderson Group PLC now owns 1,041,724 shares of the company’s stock worth $26,611,000 after acquiring an additional 313,019 shares during the period. Institutional investors own 95.08% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on ELVN. Robert W. Baird raised their price target on shares of Enliven Therapeutics from $32.00 to $40.00 and gave the stock an “outperform” rating in a research note on Friday, November 15th. BTIG Research began coverage on shares of Enliven Therapeutics in a research note on Friday, December 13th. They set a “buy” rating and a $42.00 price target for the company. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $38.25.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.